Divis Laboratories has accepted the retirement of two key senior management executives, L. Ramesh Babu and D. Madhu Babu, marking a leadership transition within its operational hierarchy. The company intimated the National Stock Exchange of India Limited and BSE Limited that both Vice Presidents will cease to be Senior Management Personnel effective from the close of business hours on July 31, 2026. This disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The departure affects two critical functional areas: procurement and projects. L. Ramesh Babu served as Vice President (Procurement), while D. Madhu Babu held the position of Vice President (Projects). Both executives are retiring from their respective roles simultaneously. The company’s Company Secretary & Compliance Officer, M. Satish Choudhury, signed the intimation letter dated July 31, 2026, confirming the cessation of their employment status.

Executive Details

The following table outlines the specific details of the retiring executives as disclosed in the filing:

Regulatory Compliance

The intimation references SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The filing confirms that there are no undisclosed relationships between directors regarding these cessations, and no brief profiles were required as this is a retirement rather than an appointment. The company stated that this information is for the records of the stock exchanges.

What This Means for Investors

The simultaneous retirement of two Vice Presidents suggests a planned succession or natural attrition rather than a sudden exodus. For a pharmaceutical manufacturer like Divis Laboratories, stability in procurement and project execution is vital for maintaining supply chain efficiency and capital expenditure timelines. Investors should monitor subsequent filings for the appointment of successors to these roles to ensure continuity in these strategic functions. The absence of any negative qualifiers or mentions of dispute indicates a routine administrative update.

Divi's Laboratories Limited has fixed July 24, 2026, as the record date to determine shareholder eligibility for a dividend of ₹30 per equity share for the financial year 2025-26. The Board of Directors recommended this payout at its meeting on May 23, 2026, subject to shareholder approval at the upcoming Annual General Meeting. The dividend of ₹30 per share on a face value of ₹2 each translates to 1,500%. If approved, payment will commence on or from August 14, 2026, subject to tax deduction at source.

The 36th Annual General Meeting is scheduled for Monday, August 10, 2026, at 10:00 A.M. IST. The meeting will be conducted through Video Conferencing (VC) and Other Audio-Visual Means (OAVM) in compliance with relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Notice of the AGM along with the Annual Report 2025-26 was sent electronically on July 15, 2026, and is also available on the company's website. Newspaper publications regarding the notice were published on July 17, 2026, in Financial Express and Andhra Prabha.

E-voting and Participation Details

The company has engaged KFin Technologies Limited to provide remote e-voting facilities. Members may cast their votes remotely from 9:00 a.m. (IST) on Thursday, August 06, 2026, till 5:00 p.m. (IST) on Sunday, August 09, 2026. A person whose name is recorded in the Register of Members or Register of Beneficial Owners as on the cut-off date, Monday, August 03, 2026, is entitled to remote e-voting or participation at the AGM. Members attending the AGM through VC/OAVM shall be reckoned for the purpose of quorum.

Shareholders are required to ensure compliance with Know Your Customer (KYC) norms to receive dividends. Payments will be processed exclusively in electronic mode. Members holding shares in physical form must ensure their folios are KYC compliant by registering PAN, contact details, bank account details, and specimen signatures with the company or its Registrar and Transfer Agent, KFin Technologies Limited. Failure to meet these requirements will result in an inability to receive the dividend.

The company has informed shareholders that dividend income is taxable in their hands under the Income Tax Act, 2025. Consequently, tax will be deducted at source at the prescribed rates. Shareholders have been requested to submit applicable declarations and documents on or before July 24, 2026. A communication regarding tax deduction was sent via email on June 10, 2026, and is available on the company's website.